Aslan004 2b：ASLAN Pharmaceuticals initiates Phase 2b study of ...
ASLAN Pharmaceuticals initiates Phase 2b study of ...
2022年2月10日—ASLANPharmaceuticalsinitiatesPhase2bstudyofASLAN004(eblasakimab)inmoderate-to-severeatopicdermatitis.PressReleases.ByLauren ...。其他文章還包含有：「AdultsWithModeratetoSevereAtopicDermatitis」、「ASLANPharmaceuticalsInitiatesPhase2bStudyofASLAN004...」、「InvestorRelations」、「News&Publications」、「Phase2bStudyofASLAN004inAdultsWithModerate」、「若2022年中將亞獅康的市值帶上10...
查看更多 離開網站
Adults With Moderate to Severe Atopic Dermatitis
https://www.clinicaltrials.gov
沒有這個頁面的資訊。
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 ...
https://www.bloomberg.com
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis o The TRials with EblasaKimab in Atopic ...
Investor Relations
https://ir.aslanpharma.com
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis. The TRials with EblasaKimab ...
News & Publications
https://aslanpharma.com
ASLAN Pharmaceuticals initiates Phase 2b study of ASLAN004 (eblasakimab) in moderate-to-severe atopic dermatitis ... ASLAN Pharmaceuticals (Nasdaq: ASLN) has ...
Phase 2b Study of ASLAN004 in Adults With Moderate
https://classic.clinicaltrials
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for ...
若2022年中將亞獅康的市值帶上10億美金
https://www.berich.com.tw
ASLAN004 2b 每組收案人數(56-59人) 比Lebrikizumab (73-80人) 少17-21人. ASLAN004 2b收案IGA3/4比59/41 (比Lebrikizumab 70/30 嚴重些) ASLAN004 2b基線四組平均EASI ...